Location: Home
  • search
  • go
  • Relate News
  • 3/11/2026Eli Lilly Plans $3B China Manufacturing Investment, Partners With Phar...
  • 3/10/2026China Patent Expiry and New GLP-1 Drugs Spark Global Obesity Drug Comp...
  • 3/10/2026India Still Relies Heavily on China for Essential Pharmaceutical Ingre...
  • 3/10/2026Novo Nordisk and United Labs Report ~20% Weight Loss With Next‑Gen Tr...
  • 3/6/2026China Approves Novo's Weekly Insulin–GLP-1 Combination Therapy for Ty...
  • 3/4/2026Eli Lilly Advances New Oral Diabetes Therapy in China
  • 2/28/2026China-SCO Cooperation Center for Metabolic Diseases Launched in Shangh...
  • 2/26/2026Jiuyuan Files for Approval of Wegovy Biosimilar in China
  • 2/25/2026Global Pharma Giants Rush to License Chinese Weight-Loss Drugs, Eye Ob...
  • 2/24/2026Pfizer Acquires China Rights to Sciwind's Approved GLP-1 Therapy
  • 2/24/2026United Labs and Novo Nordisk Post Strong Phase 2 Data for UBT251 Tripl...
  • 2/12/2026Lilly China's Mounjaro Approved for Type 2 Diabetes Monotherapy
  • 2/11/2026Shiling Pharma Targets 2028 for Nasal Spray Version of Wegovy Obesity ...
  • 2/10/2026Hengrui and Kailera Advance Obesity Therapy After Encouraging Mid-Stag...
  • 2/5/2026Novo Nordisk Reports First Decline in Ozempic Sales in Greater China
  • 1/30/2026AstraZeneca Expands Obesity Pipeline Through $18.5B CSPC Collaboration
  • 1/20/2026Hybio Wins CNY 180M GLP-1 API Order as Novo Nordisk Seen as Likely Cus...
  • 1/1/2026China's Supreme Court Upholds Semaglutide Patent, Strengthening IP Pro...
  • 1/1/2026Eli Lilly Slashes Mounjaro Price in China, Sparking Fierce Weight-Loss...
  • 12/30/2025Novo Nordisk Cuts Price of Wegovy in China Ahead of Patent Expiry
  • 12/27/2025Novo Nordisk's Wegovy Approved in China for Cardiovascular Risk Reduct...
  • 12/8/2025CSPC's Semaglutide Injection Moves Forward — sNDA Accepted, Obesity I...
  • 11/28/2025Gan & Lee Launches GRADUAL-3 Phase 3 Trial of Once-Monthly Bofanglutid...
  • 11/18/2025India and China Explore Reverse-Trade Model for Pharmaceuticals
  • 11/12/2025Indian Pharma Firms Secure Key Wins in China's Latest VBP Round
  • 11/4/2025CDE Invites Comments on the Draft Technical Guidelines for Dose Extrap...
  • 10/17/2025Dianthus Secures Exclusive Global Rights to DNTH212 from China's Leads...
  • 10/17/2025Novo vs. KBP: Fraud or Due Diligence Slipup? (FierceBiotech)
  • 10/13/2025CDE Issues Guidance to Address Common Challenges in Pediatric Drug Dev...
  • 10/13/2025Two Decades of Pediatric Drug Trials in China Reveal Progress and Pers...
  • Page:1/44 Total number of articles:1307: [First][<<] [1] [2] [3] [4] [5] [>>] [End]
  • Site map | Contact Us | Links
  • © Wicon International Group